• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267549 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 V; {6 I# X0 u  ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 1 k' H4 c+ S" K/ k  [
+ Author Affiliations$ }( }' A/ y) b1 b  s+ s
6 }/ G3 e, w" P/ r$ E# m1 V2 L5 b
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 0 O& O. |; a" ?2 S8 v
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 Z9 s$ b% [* C2 v" V
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 ~6 E6 m+ C, e$ v4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan / P( f8 ^3 v% n# X
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + i: x1 O5 l) c
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 D2 ^+ [1 E: n* k/ y0 O6 F. m7Kinki University School of Medicine, Osaka 589-8511, Japan + X, P) |  a" m$ l
8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 r% F0 ?: Z% E1 h' l" L9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 G5 |8 a" N' V* a9 S8 `; h' N
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
/ y0 [7 a; z& o8 i0 F7 b: S, ]% GAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
. a5 ~# H/ I) y. J7 m7 ^* [+ H9 W- C- O1 }1 p
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
; I- l, h( ?' k% m0 U
( `, \" m. \% q7 i3 I! }6 VAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato & L- T1 n( k5 o

0 A* W! a8 i" w" W* Z3 oAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
4 `! {/ k+ \4 {( W* B& k4 Y8 Z" C2 F, b. z9 T7 y) b
Published online on: Thursday, December 1, 2011
( ^( H* h& |, H( w2 Y3 d2 k
& g: C1 D4 ?5 H) g6 a* Q6 t& ?" K* qDoi: 10.3892/ol.2011.507 " E; C+ e5 N# E& M- R7 t
3 L" m- ^/ Y6 x5 l
Pages: 405-410
  R& K/ o$ |5 F, g" L/ o, K$ x  I& ]7 m2 G* Y) f% d/ i
Abstract:! q3 E/ J+ D8 @) F7 P
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.' p. j9 \$ F' `' \! _. S& f

8 I: _) V9 F" C9 F
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
& X! d9 v! r$ DF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
0 e5 P, C- J% `+ Author Affiliations
& p5 B4 K& U/ t: Z1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
; K* k4 b. \# q) d6 c& K5 q) m( n2Department of Thoracic Surgery, Kyoto University, Kyoto
- E: I& g6 ^( H! x, p3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
+ {) D' b% F* f. n% t& ?) z4 d&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
5 {7 `$ g$ m) O/ _% F* t% fReceived September 3, 2010.
+ O& K% _6 L  U9 |/ j# U/ G1 W, @Revision received November 11, 2010. - ^2 q) X! I( Q7 c
Accepted November 17, 2010.
$ L' S' y1 T9 t/ [; j7 R0 G5 bAbstract
) u3 V0 d* z1 d# U- X9 `' W2 u( eBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
' N: \( w% o& f6 [0 RPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 9 G# g/ ^% V% s$ A5 O# ]
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
' y0 k/ c; Y( @% }3 WConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
+ Z2 P4 K! X# C+ Z4 `& g
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。+ W* |* b1 A' O
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?/ \/ g* u6 }; R  B
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
- ~( f( M. j% T( V& a* `http://clinicaltrials.gov/ct2/show/NCT01523587) B4 a7 j. T8 K5 R$ z; @
8 Z9 D; h# R0 C  Q) `7 H5 T5 b/ m
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
' }# ^2 h" D4 E7 n3 R3 E; Zhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
/ k% c4 y" ?/ f& }% I: ~
- e& P. G2 ^6 z从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
6 V: C' F$ L9 S4 ]至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 8 G+ c- Y( }. G+ y% o1 h/ I. c, z
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
! P7 ]( P( L2 I% N; @至今为止,未出 ...
$ l4 z/ c" d% h/ e& v. M! s1 O
没有副作用是第一追求,效果显著是第二追求。' J' D) j5 z7 H. A& z- P; T
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表